You have read all your free articles, to continue reading subscribe to read the rest of this content.
Ilya Pharma has secured a total of 5.3 million EUR in funding from the European Innovation Council (EIC) Accelerator program of blended financing. The funds will enable Ilya Pharma to accelerate a Phase II Trial of its lead drug candidate ILP100 which has the potential to heal problematic non-heaAlready a…
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladdAlready a subscriber Login You have read all your free…
The company has decided to formally appoint candidate drug and prepare the preclinical safety program with Tumorad required in preparation for clinical trials. Spago Nanomedical has demonstrated, with statistical significance, that Tumorad reduces tumor growth and extends survival in a mice modelAlready a subscriber Login You have read all your…
Novo Nordisk has announced plans to invest DKK 850 million in expanding its production facilities in Kalundborg, Denmark. This new investment brings Novo Nordisk’s total investments in site Kalundborg to more than DKK 2 billion in 2020. Novo Nordisk currently manufactures a range of diabetes caAlready a subscriber Login You…
